Nav: Home

Histologic classification impacts SBRT treatment in early-stage lung cancer patients

December 22, 2016

DENVER - Early-stage non-small cell lung cancer (NSCLC) patients with squamous cell carcinoma (SqCC) have a significantly higher rate of local failure after stereotactic body radiation therapy (SBRT) than other NSCLC histological subtypes.

Lung cancer is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for roughly 85% of lung cancers. Surgical resection is the standard treatment of early-stage (stage I, II) lung cancers. However, a subset of early-stage patients will be unable to tolerate surgery due to their age, location of tumor, or medical comorbidities. SBRT is a noninvasive, high-precision radiation delivery technique of a few (or even a single) high-dose fractions to small areas or tumors that has become established as the standard of care in medically inoperable patients. NSCLC is composed of several histological subtypes that effect the genetic and microenvironments of tumors, and the impact of histology or tumor heterogeneity on SBRT treatments is not very well understood.

A group of researchers from Cleveland Clinic in Cleveland, Ohio, USA analyzed 740 patients from an institutional review board-approved database of early-stage NSCLC patients treated with SBRT from 2003 through 2015 to investigate the impact of histological subtype and tumor heterogeneity on SBRT treatment. Patients were grouped into four categories by tumor type: adenocarcinoma, SqCC, unknown, and NSCLC not otherwise specified (NOS). The unknown group included patients who did not undergo a tissue biopsy and those with a nondiagnostic biopsy result. The NSCLC NOS group included patients with large cell carcinoma and NSCLC NOS. Patients were well balanced for patient age, sex, BMI, performance status, length of follow-up, and radiotherapy (RT) dose. Cumulative incidence curves (CICs) for local failure, defined as radiographic progression with or without positive biopsy results within 1 cm of the planning target volume (PTV), were estimated using the competing risk method. Predictors of local failure were estimated using Fine and Gray regression. Actuarial analysis was used to estimate rates of overall survival (OS), and the Kaplan-Meier method was used to generate OS curves.

The results of the study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), show that of the 740 eligible patients 32% were characterized as adenocarcinoma, 29% as SqCC, 30% as unknown, and 8% as NSCLC NOS. Overall, 72 patients had a local failure, with a cumulative incidence of local failure at 3 years of 11.8%. Univariate analysis demonstrated that SqCC histological subtype, younger age, fewer medical comorbidities, higher body mass index, higher positron emission tomography standardized uptake value, central tumors, and lower radiation dose were associated with an increased risk for local failure. Multivariate analysis identified SqCC histological subtype (hazard ratio = 2.4, p = 0.008) as the strongest predictor of local failure. Three year cumulative rates of local failure demonstrated that patients with SqCC (18.9% (95% CI: 12.7-25.1)) failed SBRT at a significantly higher rate than those with adenocarcinomas (8.7% (95% CI: 4.6-12.8)), or NSCLC NOS (4.1% (95% CI: 0-9.6)).

The authors comment that, "This study is the first demonstration of a histological basis for local failure after SBRT. The results demonstrate that SqCC have a significantly higher rate of local failure after SBRT than other NSCLCs do. The local failure rate for SqCC was twofold higher than for adenocarcinomas. These results suggest that SqCCs are more resistant to SBRT than other NSCLCs are. The clinically significant implication of our study is that SBRT treatments should be optimized on the basis of histological subtype."
-end-
Co-authors Gregory Videtic and Mohamed Abazeed are members of IASLC.

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit http://www.iaslc.org for more information.

Written by: Jacinta Wiens, PhD, 720-598-1941; jacinta.wiens@iaslc.org
Media Contact: Becky Bunn, 720-254-9509; Becky.Bunn@iaslc.org

International Association for the Study of Lung Cancer

Related Lung Cancer Articles:

AI helps to fight against lung cancer
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
High levels of estrogen in lung tissue related to lung cancer in postmenopausal women
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.

Related Lung Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...